These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 39305969)

  • 21. Changes in synaptic markers after administration of ketamine or psychedelics: a systematic scoping review.
    Zhornitsky S; Oliva HNP; Jayne LA; Allsop ASA; Kaye AP; Potenza MN; Angarita GA
    Front Psychiatry; 2023; 14():1197890. PubMed ID: 37435405
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Psychedelics and Hallucinogens in Psychiatry: Finding New Pharmacological Targets.
    Sousa TR; Rema J; Machado S; Novais F
    Curr Top Med Chem; 2022; 22(15):1250-1260. PubMed ID: 34852736
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypothesis: The Psychedelic Ayahuasca Heals Traumatic Memories via a Sigma 1 Receptor-Mediated Epigenetic-Mnemonic Process.
    Inserra A
    Front Pharmacol; 2018; 9():330. PubMed ID: 29674970
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Systematic Review of the Neurocognitive Effects of Psychedelics in Healthy Populations: Implications for Depressive Disorders and Post-Traumatic Stress Disorder.
    Velit-Salazar MR; Shiroma PR; Cherian E
    Brain Sci; 2024 Mar; 14(3):. PubMed ID: 38539636
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dosing Psychedelics and MDMA.
    Liechti ME; Holze F
    Curr Top Behav Neurosci; 2022; 56():3-21. PubMed ID: 34734392
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evidence on the impairing effects of Ayahuasca on fear memory reconsolidation.
    Daneluz DM; Sohn JMB; Silveira GO; Yonamine M; Stern CA
    Psychopharmacology (Berl); 2022 Oct; 239(10):3325-3336. PubMed ID: 36069952
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Psychedelic Therapy: A Primer for Primary Care Clinicians-Historical Perspective and Overview.
    Tabaac BJ; Shinozuka K; Arenas A; Beutler BD; Cherian K; Evans VD; Fasano C; Muir OS
    Am J Ther; 2024 Mar-Apr 01; 31(2):e97-e103. PubMed ID: 38518266
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exploring the regulatory framework of psychedelics in the US & Europe.
    Behera HK; Joga R; Yerram S; Karnati P; Mergu T; Gandhi K; M S; Nathiya D; Singh RP; Srivastava S; Kumar S
    Asian J Psychiatr; 2024 Sep; 102():104242. PubMed ID: 39305768
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ayahuasca-enhanced extinction of fear behaviour: Role of infralimbic cortex 5-HT
    Werle I; Nascimento LMM; Dos Santos ALA; Soares LA; Dos Santos RG; Hallak JEC; Bertoglio LJ
    Br J Pharmacol; 2024 Jun; 181(11):1671-1689. PubMed ID: 38320596
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis.
    Yao Y; Guo D; Lu TS; Liu FL; Huang SH; Diao MQ; Li SX; Zhang XJ; Kosten TR; Shi J; Bao YP; Lu L; Han Y
    Psychiatry Res; 2024 May; 335():115886. PubMed ID: 38574699
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice.
    Halberstadt AL; Koedood L; Powell SB; Geyer MA
    J Psychopharmacol; 2011 Nov; 25(11):1548-61. PubMed ID: 21148021
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of the 5-HT
    Jaster AM; Elder H; Marsh SA; de la Fuente Revenga M; Negus SS; González-Maeso J
    Psychopharmacology (Berl); 2022 Jun; 239(6):1665-1677. PubMed ID: 35233648
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Neurotrophic mechanisms of psychedelic therapy].
    Corne R; Mongeau R
    Biol Aujourdhui; 2019; 213(3-4):121-129. PubMed ID: 31829932
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The use of classic psychedelics among adults: a Danish online survey study.
    Søgaard Juul T; Ebbesen Jensen M; Fink-Jensen A
    Nord J Psychiatry; 2023 May; 77(4):367-378. PubMed ID: 36173202
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Survey of subjective "God encounter experiences": Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT.
    Griffiths RR; Hurwitz ES; Davis AK; Johnson MW; Jesse R
    PLoS One; 2019; 14(4):e0214377. PubMed ID: 31013281
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review.
    Breeksema JJ; Kuin BW; Kamphuis J; van den Brink W; Vermetten E; Schoevers RA
    J Psychopharmacol; 2022 Oct; 36(10):1100-1117. PubMed ID: 36017784
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and Safety of Psychedelics in Treating Anxiety Disorders.
    Feulner L; Sermchaiwong T; Rodland N; Galarneau D
    Ochsner J; 2023; 23(4):315-328. PubMed ID: 38143548
    [No Abstract]   [Full Text] [Related]  

  • 38. The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder.
    Rosenblat JD; Husain MI; Lee Y; McIntyre RS; Mansur RB; Castle D; Offman H; Parikh SV; Frey BN; Schaffer A; Greenway KT; Garel N; Beaulieu S; Kennedy SH; Lam RW; Milev R; Ravindran AV; Tourjman V; Ameringen MV; Yatham LN; Taylor V
    Can J Psychiatry; 2023 Jan; 68(1):5-21. PubMed ID: 35975555
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Noradrenergic enhancement of reconsolidation in the amygdala impairs extinction of conditioned fear in rats--a possible mechanism for the persistence of traumatic memories in PTSD.
    Dębiec J; Bush DE; LeDoux JE
    Depress Anxiety; 2011 Mar; 28(3):186-93. PubMed ID: 21394851
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Psilocybin and Other Classic Psychedelics in Depression.
    Nutt DJ; Peill JM; Weiss B; Godfrey K; Carhart-Harris RL; Erritzoe D
    Curr Top Behav Neurosci; 2024; 66():149-174. PubMed ID: 37955822
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.